When employers only offer high-deductible health plans, they reduce costs by reducing utilization. However, consumers reduce their use of essential as well as nonessential services, which is sub-optimal for their long-term health, explained Niteesh Choudhry, MD, PhD, associate professor of medicine at Harvard Medical School.
When employers only offer high-deductible health plans, they reduce costs by reducing utilization. However, consumers reduce their use of essential as well as nonessential services, which is sub-optimal for their long-term health, explained Niteesh Choudhry, MD, PhD, associate professor of medicine at Harvard Medical School.
Transcript (modified)
Some employers are making the move to only offer high-deductible health plans. What would be the impact of that?
We know a bunch of things about high-deductible health plans right now, and most of the literature comes from those high full-replacement kinds of plans where employers one day say “Okay, everybody’s being shifted to a higher-deductible product.”
So the first thing that we know is that they definitely reduce spending and so they do what they’re intended to do. They’re designed to save the employer’s money—the best estimates that we have is at about $500 per member per year is what they end up doing, so that’s successful. They do that by reducing utilization more than anything else, so they reduce the use of all kinds of services: medications, radiology, emergency rooms, office visits, and so on.
The positive side, again the reduction in cost, is really a facet of reduction in utilization. On the negative side, what we know is that the reduction in utilization is both for services that we would call “low value,” or less essential or nonessential, as well as for services that appear to be essential. And so people end up making choices that are sub-optimal for at least their long-term health, or perhaps even their short-term pain or suffering, because of the nature of the benefit design.
The benefit design, as they’re intended to do, means that more people are put at risk for short-term costs and financial burden, and the literature we have says that people actually struggle a little bit more when they’re on these plans as compared to traditional plans.
Redefining Long COVID Care With Personalized Treatment
March 20th 2025To mark the 5-year anniversary of the COVID pandemic, The American Journal of Managed Care® spoke with Noah Greenspan, DPT, PT, CCS, EMT-B, cardiopulmonary physical therapist and director of the Pulmonary Wellness and Rehabilitation Center in New York City.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
How Mirdametinib Improves QOL for People With NF1-Associated Plexiform Neurofibromas
March 18th 2025Christopher L. Moertel, MD, University of Minnesota, discusses the trial data that helped get mirdametinib approved and what providers can do to keep measuring quality of life (QOL) improvements.
Read More
Advances in Gene Therapy, Neuroregeneration at the Forefront of MDA 2025
March 13th 2025Look ahead to this year's Muscular Dystrophy Association (MDA) meeting, which will feature discussions on the latest gene therapies, clinical trial data, policy considerations, and more in the realm of neuromuscular disease.
Read More